This phase I study was designed to determine the maximum tolerated dose (MTD) and dose-limiting side effects of combination treatment with paclitaxel (Taxol) and UFT (uracil and tegafur in a 4:1 molar ratio) plus oral
Stephanie Lang, MD
Advertisement
Articles by Stephanie Lang, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
TERN-701 Earns FDA Breakthrough Therapy Designation in Ph+ CML
2
Duvelisib Shows Significant Activity in R/R Peripheral T-Cell Lymphoma
3
ASCO Releases New Patient-Clinician Communication Guidelines
4
In Vivo CAR Engineering and the Next Phase of Cellular Immunotherapy
5